Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.54 USD | +1.60% | +8.09% | +9.01% |
Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.01% | 35.25M | |
+26.61% | 661B | |
+27.32% | 566B | |
-6.35% | 352B | |
+20.40% | 332B | |
+3.43% | 283B | |
+14.36% | 231B | |
+5.22% | 200B | |
-9.04% | 195B | |
-4.79% | 145B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- Vyne Therapeutics Says Vitiligo Drug Candidate Has No Negative Effect on Platelet Count in Phase 1a Trial; Shares Rise